Phaik Lyn Oh
About Phaik Lyn Oh
Phaik Lyn Oh is a Scientist I specializing in Oncology Research at CytomX Therapeutics, where she has worked since 2020. She has a background in Food Science and Technology, holding a Ph.D. from the University of Nebraska-Lincoln, and has previously held positions at Bayer Pharmaceuticals and CytomX Therapeutics.
Current Role at CytomX Therapeutics
Phaik Lyn Oh serves as Scientist I in Oncology Research at CytomX Therapeutics. In this role, she contributes to the identification and validation of novel targets to enhance the company's research pipeline. Additionally, she leads the development of second-generation probody drug conjugates (PDCs) and multi-specific antibodies. Her work focuses on advancing innovative therapeutic solutions in oncology.
Previous Experience at Bayer Pharmaceuticals
Phaik Lyn Oh has extensive experience at Bayer Pharmaceuticals, where she held multiple positions. She worked as a Research Associate from 2014 to 2016, followed by a role as Research Scientist (Technical) from 2016 to 2018. She then transitioned to a Staff Research Scientist (Technical) position for one year in 2018 to 2019. All these roles were based in the San Francisco Bay Area, contributing to her expertise in the pharmaceutical industry.
Education and Expertise
Phaik Lyn Oh earned her Doctor of Philosophy (Ph.D.) in Food Science and Technology from the University of Nebraska-Lincoln. She also holds a Bachelor's Degree in Biological Sciences from the same institution. Her educational background provides a strong foundation for her work in oncology research and drug development.
Career Progression in Oncology Research
Phaik Lyn Oh's career in oncology research began at CytomX Therapeutics, where she initially worked as an Associate Scientist from 2019 to 2020 before advancing to her current position as Scientist I. Her progression reflects her growing expertise and contributions to the field, particularly in the development of innovative drug conjugates.